Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=5&sort=-funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=-funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=6&sort=-funder", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=4&sort=-funder" }, "data": [ { "type": "Grant", "id": "10671", "attributes": { "award_id": "1U01IP001194-01", "title": "RFA-IP-22-004, US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2027-09-29", "award_amount": 987989, "principal_investigator": { "id": 26731, "first_name": "EMMANUEL B", "last_name": "WALTER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "– Duke Human Vaccine Institute Duke University is pleased to respond to RFA-IP-22-004 entitled “US Platform to Measure the Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings” by submitting the application for Component B. Duke University will coordinate the activities of the Centers for Disease Control and Prevention’s Respiratory Virus Vaccine Effectiveness Network incorporating the collective breadth of scientific, program management, regulatory, data management, statistical, and information technology expertise of the Duke Human Vaccine Institute (DHVI). In particular, we will leverage our vast prior experience coordinating clinical investigations for both NIAID and the CDC to help facilitate the work of this project. The Duke Network Coordinating Center (NCC) will provide logistical and coordinating support by facilitating network communications through hosting video and in-person conferences, hosting a network SharePoint, providing reports and project updates and establishing a clear communication plan for network activities. As the NCC, The DHVI will help facilitate protocol development and establish standard operating procedures for network investigations. Studies will include evaluations of both influenza and SARS-CoV-2 vaccine effectiveness at preventing symptomatic respiratory infection in the community and household settings. As the NCC, the DHVI is also well poised to support network studies assessing vaccine immunogenicity in addition to studies using more complex virologic and immunologic influenza assays to detect influenza virus infection and the host immune response to infection. Working with the Duke University Health System IRB, the Duke NCC will provide the regulatory support to facilitate single IRB requirements. Through our established quality management programs, we will also assure that network studies are performed in a manner which adhere to good clinical practice. The Duke NCC will provide data management and statistical support for network studies. Duke will build and host project specific REDCap databases from which information can be readily exported to provide project updates through dashboards. Data exports will also be utilized to create reports, presentations and manuscripts to disseminate information regarding the current effectiveness of the respiratory virus vaccine being evaluated given the circulating virus strains or variants.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10567", "attributes": { "award_id": "1R43MH130305-01A1", "title": "A novel digital platform for measurement-based peer supervision of non-specialist providers conducting brief psychological interventions", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 26585, "first_name": "Maggie", "last_name": "Sweeney", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-07", "end_date": "2023-09-06", "award_amount": 259467, "principal_investigator": { "id": 22839, "first_name": "Y. Xian XIAN", "last_name": "Ho", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1543, "ror": "", "name": "DIMAGI, INC.", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 26586, "first_name": "Neal", "last_name": "Lesh", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1543, "ror": "", "name": "DIMAGI, INC.", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Unmet mental health needs continue to be a significant public health challenge in the US and the increase in reported adverse mental health conditions associated with the onset of the Covid-19 pandemic have likely exacerbated this problem. We propose a reverse innovation solution to digitize an evidence-based task sharing approach for treating depression in individuals from underserved communities, where health inequities are most pronounced due to a shortage of mental health specialists and lack of access to resources. The digital platform will be designed to host a suite of tools to support measurement-based peer supervision (MBPS), which includes the ability for non-specialist providers (NSPs) to record therapy sessions, rate sessions using a validated quality scale, and review ratings safely and securely with peers in moderated group discussions. Target end users will be NSPs who are trained on a behavioral activation program which has been successfully implemented in India to treat depression. The goal of this Phase I project is to demonstrate acceptability and feasibility of the proposed digital solution. We will address this goal with two specific aims. In Aim 1, we will work in close collaboration with experts in MBPS and an advisory group of NSPs to determine design requirements and develop a prototype of the digital solution. In Aim 2, a purposive sample target end users (i.e., NSPs trained in behavioral activation) will test the prototype developed in Aim 1. We will use mixed methods (interviews, surveys, passive usage data) to probe usability and user experience and identify barriers and facilitators to implementation. Results from Phase I will inform a potential Phase II project to study the digital platform’s implementation at scale and its effect on NSP performance with the long-term goal of improving mental health outcomes, particularly in hard-to-reach communities that can benefit the most from NSP-led support.", "keywords": [ "Address", "Behavioral", "Benchmarking", "COVID-19 pandemic", "Caring", "Collaborations", "Communities", "Community Health Aides", "Data", "Data Storage and Retrieval", "Development", "Effectiveness", "Ensure", "Feedback", "Focus Groups", "Future", "Goals", "Group Interviews", "Group Structure", "Health Personnel", "Incidence", "India", "Individual", "Industry", "Intervention", "Interview", "Measurement", "Measures", "Mental Depression", "Mental Health", "Mental Health Services", "Methods", "Nurses", "Outcome", "Paper", "Participant", "Peer Group", "Performance", "Persons", "Phase", "Predictive Analytics", "Primary Care Physician", "Prize", "Process", "Professional counselor", "Provider", "Psychiatrist", "Psychologist", "Public Health", "Qualitative Methods", "Quality of Care", "Readiness", "Recommendation", "Recovery", "Reporting", "Resources", "Sampling", "Secure", "Self Efficacy", "Series", "Services", "Small Business Innovation Research Grant", "Specialist", "Standardization", "Supervision", "Support System", "Surveys", "System", "Testing", "Texas", "Therapeutic", "Training", "Travel", "Work", "acceptability and feasibility", "base", "behavioral health", "commercialization", "cost", "depressive symptoms", "design", "digital", "effectiveness evaluation", "effectiveness measure", "evidence base", "experience", "field study", "gaps in access", "health inequalities", "implementation facilitators", "improved", "innovation", "insight", "intervention program", "iterative design", "medical schools", "member", "mobile application", "novel", "peer", "programs", "promoter", "prototype", "psychologic", "quality assurance", "skill acquisition", "statistics", "success", "teacher", "therapy duration", "tool", "underserved community", "usability", "web app" ], "approved": true } }, { "type": "Grant", "id": "10607", "attributes": { "award_id": "75N92022D00013-P00002-759202200001-1", "title": "NIBIB, INNOVATION FUNNEL FOR MATERNAL HEALTH -RADx", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-01", "end_date": "2024-02-29", "award_amount": 338000, "principal_investigator": { "id": 23973, "first_name": "MARK", "last_name": "MARINO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1670, "ror": "https://ror.org/00mgk5c15", "name": "VentureWell", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1670, "ror": "https://ror.org/00mgk5c15", "name": "VentureWell", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "NICHD, in partnership with the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the NIH Office of the Director, aims to leverage the RADx Tech program’s innovation funnel design—which was used by NIBIB to speed the development, commercialization and implementation of COVID-19 testing technologies—to accelerate the development of diagnostic devices, wearables, or other remote sensing technologies that can reduce SMM/MM for individuals residing in maternity care deserts during the first year of the postpartum period (namely, from day of delivery or end of pregnancy). The innovation funnel approach uses stage-gated, milestone-based award payments to compress the customary technology development timeline. this is accomplished by employing, in parallel, expert teams to address scientific/technical, regulatory, clinical, and commercialization requirements to validate, de-risk, scale up, manufacture, and deploy novel tests through seamless pipeline. Successful outputs from this Challenge may include technologies such as wearable devices, smartphone-enabled diagnostic tools, integrated sensor technologies, and diagnostic devices or tests for use at-home or at the point-of-care (POC). Solutions generated by innovators shall allow continuity of monitoring when access to care providers is limited and extend diagnostic and monitoring capabilities to support timely return to maternity care when necessary. Priority conditions for prediction, detection, diagnosis, and monitoring during the postpartum period may include cardiovascular diseases (such as cardiomyopathies), hemorrhage, sepsis, and mental health conditions (such as postpartum depression), which are recognized as associated with high rates of severe morbidity and mortality during the first year after delivery or end of pregnancy.", "keywords": [ "Address", "Award", "COVID-19 testing", "Cardiomyopathies", "Cardiovascular Diseases", "Caring", "Cellular Phone", "Clinical", "Detection", "Development", "Diagnosis", "Diagnostic", "Diagnostic Equipment", "Diagnostic tests", "Health Services Accessibility", "Hemorrhage", "Home", "Individual", "Maternal Health", "Maternal Health Services", "Maternal Mortality", "Mental Health", "Monitor", "Morbidity - disease rate", "National Institute of Biomedical Imaging and Bioengineering", "National Institute of Child Health and Human Development", "Output", "Postpartum Depression", "Postpartum Period", "Pregnancy", "Pregnancy Outcome", "Prize", "Publications", "Publishing", "RADx", "RADx Tech", "Risk", "Sepsis", "Speed", "Technology", "Testing", "Time", "TimeLine", "United States National Institutes of Health", "Vision", "base", "care providers", "commercialization", "design", "diagnostic technologies", "diagnostic tool", "innovation", "mortality", "novel", "payment", "point of care", "programs", "remote sensing", "scale up", "sensor technology", "severe maternal morbidity", "technology development", "wearable device" ], "approved": true } }, { "type": "Grant", "id": "10495", "attributes": { "award_id": "75N93022C00047-0-9999-1", "title": "REAL-TIME SURVEILLANCE OF VACCINE MISINFORMATION FROM SOCIAL MEDIA PLATFORMS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-08-08", "end_date": "2023-08-07", "award_amount": 300000, "principal_investigator": { "id": 26502, "first_name": "JINGCHENG", "last_name": "DU", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1763, "ror": "", "name": "MELAX TECHNOLOGIES, INC.", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "To develop digital tools to identify and combat malicious digital bots that spread misinformation about infectious disease treatments and vaccines, including COVID-19 vaccines.", "keywords": [ "Basic Science", "COVID-19 vaccine", "Coronavirus", "Misinformation", "Severe Acute Respiratory Syndrome", "Time", "Vaccines", "combat", "digital", "infectious disease treatment", "social media", "tool" ], "approved": true } }, { "type": "Grant", "id": "10655", "attributes": { "award_id": "1U54CA272205-01", "title": "University of Maryland First Program", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-09", "end_date": "2027-08-31", "award_amount": 70373, "principal_investigator": { "id": 26713, "first_name": "Marey R.", "last_name": "Shriver", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 793, "ror": "", "name": "UNIVERSITY OF MARYLAND BALTIMORE", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "SPECIFIC AIMS African American/Black, Hispanic/Latinx, American Indian, and Alaska Native individuals make up 34% of the population, however they are underrepresented in the biomedical sciences. Underrepresented minorities (URM) make up 15% of PhD graduates and representation further along the pipeline in academia shows further attrition with URMs comprising only 9% of Assistant Professor and 4% of tenured faculty positions. Lastly, URM scientists receive only 6% of NIH research grants which are a necessity for establishing and maintaining a successful research career. The inability to maintain a diverse pool of faculty who conduct biomedical and health related research has wide spread implications. Increasing representation within research institutions will allow academic medicine to meet the needs of a diverse nation and address persistent health inequities and disparities, such as those illustrated by the COVID-19 pandemic. To address the critical gap of underrepresentation, institutional strategies must establish equitable and inclusive recruitment and faculty development that directly address existing barriers to this population. The University of Maryland School of Medicine (UMSOM) and the University of Maryland Baltimore County (UMBC) have longstanding individual and collaborative efforts to increase diversity, equity, and inclusion in the biomedical sciences, with programs supporting trainees from middle school to graduate and medical school training. Collectively UMSOM & UMBC pipeline programs and partnerships stemming from these programs have increased the recruitment of UR students and enhanced trainee diversity at all levels; however, recruitment and retention of faculty from underrepresented groups signifies a key gap in this trajectory. Currently, at UMSOM and UMBC URMs make up only 5.3% and 12% of total tenure track faculty, respectively. URM in the biomedical sciences have expressed low representation leads to social and professional isolation. Lack of critical mass of minority faculty, coordinated programs and resources to support retention and promotion, and senior leader who serve as diversity champions have been identified as key barriers to the recruitment, retention, and promotion of URM faculty. To address existing barriers to URM faculty retention and promotion we will build off prior experience from UMBC’s nationally renowned Meyerhoff Scholars Program. The success of students within the Meyerhoff Scholars Program has been attributed to addressing 4 critical factors: academic and social integration, knowledge and skill development, support and motivation, and monitoring and advising. The overall goal of the faculty development core is to transform our faculty development approach through adaptation of the Meyerhoff model using coordinated programs and resources to: 1) support the development, retention, and promotion of URM faculty, 2) create a network of senior leaders who serve as diversity champions to sustain inclusion and equity and, 3) over the long term increase the critical mass of URM faculty within the University of Maryland. Towards this goal, the specific aims of the faculty development core are: • To ensure the University of Maryland (UM) FIRST faculty cohorts achieve academic & social Integration. We will utilize existing campus networks and events, combined with individual support for integration, to ensure UM FIRST faculty are included within the fabric of their academic department and institution. In addition, a pilot grant program will encourage academic integration through the formation of new collaborations between UM FIRST and UMSOM and UMBC investigators. • To use monitoring & advising of UM FIRST faculty cohort progress to support long term success. We will combine individual development plans, mentoring committees, and administrative support to provide continual monitoring and support for UM FIRST faculty career progression. • To ensure UM FIRST faculty develop skills & knowledge in scientific writing, grant writing, and scientific management, leadership, and teaching. UM FIRST faculty will participate in a pre-defined curriculum, the FIRST Curriculum, that will focus on developing the skills and knowledge essential for an independent research career, including the required milestones to achieve promotion and tenure. Informed by their IDP and mentoring committee, UM FIRST faculty will select the most appropriate training based on their current needs in each of the following focus areas: 1) scientific writing; 2) grant writing; and 3) scientific management, leadership, and teaching. • To provide support & motivation to the UM FIRST faculty cohort through peer-mentoring and individual coaching. UM FIRST faculty will participate in peer mentoring groups and receive individual coaching to receive support while pursuing their professional and research goals. By adapting the Meyerhoff model for faculty development we will implement a scalable model to increase coordinated programs and resources to support retention and promotion of URM and create a network of senior leaders who serve as diversity champions. The success of the UM FIRST program is central to the mission of both institutions and a key priority to establish a critical mass of diverse faculty while continuing to enhance equity and inclusion, specifically in the recruitment, retention, and promotion of URM faculty on both campuses.", "keywords": [ "Academia", "Address", "African American", "Alaska Native", "American Indians", "Area", "Baltimore", "Biomedical Research", "Black American", "COVID-19 pandemic", "Cancer Biology", "Collaborations", "Communicable Diseases", "County", "Development", "Development Plans", "Doctor of Philosophy", "Educational Curriculum", "Educational process of instructing", "Engineering", "Ensure", "Event", "Faculty", "Goals", "Grant", "Health", "Hispanic", "Immunology", "Individual", "Inosine Diphosphate", "Institution", "Joints", "Knowledge", "Latinx", "Leadership", "Maryland", "Medicine", "Mentors", "Microbiology", "Minority", "Mission", "Modeling", "Monitor", "Motivation", "NCI Scholars Program", "Neurosciences", "Population", "Positioning Attribute", "Research", "Research Personnel", "Research Project Grants", "Resources", "STEM program", "Science", "Students", "Teacher Professional Development", "Technology", "Textiles", "Training", "Underrepresented Minority", "Underrepresented Populations", "Underrepresented Students", "United States National Institutes of Health", "Universities", "Writing", "base", "career", "cohort", "diversity and equity", "experience", "health disparity", "health inequalities", "junior high school", "medical schools", "member", "minority scientist", "peer coaching", "professor", "programs", "recruit", "skill acquisition", "skills", "social", "social integration", "stem", "success", "tenure track", "undergraduate student" ], "approved": true } }, { "type": "Grant", "id": "5363", "attributes": { "award_id": "5R01NR019944-02", "title": "Intensifying Community Referrals for Health: The SINCERE Intervention to Address COVID-19 Health Disparities", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Alcohol Abuse and Alcoholism (NIAAA)" ], "program_reference_codes": [], "program_officials": [ { "id": 18804, "first_name": "AMANDA ALISE", "last_name": "Price", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-05-14", "end_date": "2025-03-31", "award_amount": 742753, "principal_investigator": { "id": 18806, "first_name": "Andrea Schneider", "last_name": "Wallace", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 202, "ror": "https://ror.org/03r0ha626", "name": "University of Utah", "address": "", "city": "", "state": "UT", "zip": "", "country": "United States", "approved": true }, "abstract": "In an effort to slow transmission of the 2019 novel coronavirus (COVID-19, or COVID), communities worldwide have implemented strict quarantine policies. While these efforts appear to be having a positive public health impact, they are negatively impacting economies, limiting personal resources for both COVID+ and non- COVID infected patients, and exacerbating health disparities. Community service providers report steady increases in calls for resources (e.g., for food, housing, transportation) during the COVID-19 pandemic, particularly from underserved and underrepresented communities, and additional strain is being placed on health systems. There is a critical need to identify how to overcome community service access barriers during COVID-19, particularly for underserved communities. Our program of research has successfully leveraged existing, low-cost technology to conduct social needs screening during busy emergency department (ED) care, follow-up by United Way 211’s community referral service, and data exchange between systems, suggesting it may be a solution for understanding and meeting the needs of vulnerable and underserved patients during the COVID-19 pandemic. However, findings from our recent sample of approximately 5000 patients screened for social needs during ED visits and qualitative data from service providers, 211 community information specialists, ED Staff, and patients reveal that effectively addressing social needs and connecting to community service providers requires thoughtful, targeted approaches in order to develop relationships among patients and those involved in screening and outreach. Using a pragmatic trial approach in a sample of 1500 patients screened for social needs in ED and community-based and mobile COVID testing sites, the objective of this real world efficacy (NIH stage 3) study is to determine whether community service use for those with social needs improves general and COVID-related health outcomes, and whether random assignment to intensive follow-up and collaborative goal setting helps overcome barriers to community service use. We hypothesize that patients who use community services to meet social needs will experience improvement in general and COVID-specific health outcomes, and that patients randomized to a collaborative goal setting process with a 211 information specialist will have greater community service use. Given the unknown timeframe for social distancing measures needed during the months or years ahead, it is critical to broadly understand the barriers to, and facilitators of, COVID-19 prevention; and of how to address effects on social, mental, and physical wellbeing among COVID-19 vulnerable and socioeconomically disadvantaged populations.", "keywords": [ "2019-nCoV", "Accident and Emergency department", "Address", "Affect", "Age", "Anxiety", "Behavior", "COVID testing", "COVID-19", "COVID-19 health disparity", "COVID-19 pandemic", "COVID-19 prevention", "COVID-19 susceptibility", "Characteristics", "Charge", "Clinic", "Clinic Visits", "Clinical", "Communities", "Community Services", "Computer software", "Country", "Data", "Drops", "Emergency Care", "Emergency Department patient", "Emergency department visit", "Emotional", "Environment", "Ethnic Origin", "Food", "Gender", "Goals", "Health", "Health Services Accessibility", "Health Status", "Health system", "Hospitalization", "Housing", "Individual", "Information Specialists", "Intervention", "Interview", "Language", "Location", "Measures", "Mental Depression", "Methods", "Modeling", "Motivation", "Outcome", "Patients", "Personal Satisfaction", "Play", "Policies", "Population", "Preventive", "Process", "Protocols documentation", "Psyche structure", "Public Health", "Quarantine", "Race", "Randomized", "Reporting", "Research", "Resources", "Role", "Rural", "SARS-CoV-2 transmission", "Sampling", "Services", "Site", "Social Distance", "System", "Technology", "Telephone", "Testing", "Transportation", "Underserved Population", "United States National Institutes of Health", "Vaccines", "base", "behavioral economics", "community based service", "coping", "coronavirus disease", "cost", "data exchange", "disadvantaged population", "economic impact", "effectiveness evaluation", "efficacy study", "experience", "follow-up", "health care availability", "health disparity", "health disparity populations", "health information technology", "health service use", "improved", "meetings", "outreach", "patient engagement", "patient screening", "post-COVID-19", "pragmatic trial", "programs", "referral services", "response", "screening", "screening services", "service providers", "social", "social determinants", "socioeconomic disadvantage", "transmission process", "treatment arm", "treatment as usual", "underserved community" ], "approved": true } }, { "type": "Grant", "id": "10639", "attributes": { "award_id": "3U54CA260581-02S1", "title": "Admin-Core-001", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 26691, "first_name": "Raymond D.", "last_name": "Harris", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2025-08-31", "award_amount": 439872, "principal_investigator": { "id": 26692, "first_name": "JAMES E", "last_name": "Robinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 811, "ror": "", "name": "TULANE UNIVERSITY OF LOUISIANA", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true }, "abstract": "Overall Summary The SARS-CoV-2 virus, the causative agent of COVID-19, has infected a reported 13,810,247 persons globally as of July 16, 2020 with a mortality rate of 4.2%. In the State of Louisiana, over 7.3% of the 86,411 COVID-19 cases involve people living with cancer. Theoretically, convalescent plasma contains protective antibodies that neutralizes virus and mitigates its pathogenic effects. Yet, there remains a large gap in our understanding of the mechanisms that drive humoral and cellular immune responses and how these responses correlate with disease course and protection as well as the durability of those responses. Furthermore, there is a need for serological assays that measure these responses accurately for serodiagnosis and as correlates of immunity and protection. Without this knowledge, the true efficacy of convalescent plasma as therapy for COVID-19 and our understanding of the humoral immune response to SARS-CoV-2, especially in immunocompromised patients, will remain unknown. The overall goal of the Tulane University Convalescent Antibody and Immunity Network (TUCAIN) is to characterize this response with respect to functionality and durability. We will achieve this goal by investigating the following broad specific aims: (1) Characterize the evolution, function and longevity of the humoral immune response to COVID-19. (2) Identify cell mediated immune responses that contribute to durable or short-lived humoral immunity to SARS CoV-2. (3) Correlate protective and potentially pathogenic immune responses to the clinical course of hospitalized COVID-19 patients. We will achieve these goals by studying a diverse cohort of COVID-19 survivors and minimally sick seroconverters, including a large cohort of patients with malignancies. Using serial blood collections, we will apply several immunological technologies to study the evolution and durability of the immune response over time. We will also correlate these responses to patient outcomes and disease pathogenesis using a “big data”, systems biology approach. An approach, such as the one we propose, will allow us to determine if COVID-19 survivors develop long-term, antibody-based protection and we can confirm if convalescent plasma has therapeutic potential. This research will allow us to identify new targets for medicines and vaccines, inform personalized treatment strategies such as those required by immunocompromised patients with cancer, and to provide novel immunological algorithms applicable to a wide range of human pathogens.", "keywords": [ "2019-nCoV", "Address", "Advanced Development", "Algorithms", "Antibodies", "Antibody Response", "Antibody-mediated protection", "Applied Research", "Big Data", "Blood", "Blood specimen", "COVID-19", "COVID-19 patient", "COVID-19 survivors", "COVID-19 treatment", "Cellular Immunity", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Clinical Data", "Collection", "Data", "Data Set", "Development", "Diagnosis", "Disease", "Evolution", "Funding", "Goals", "Humoral Immunities", "Immune response", "Immunity", "Immunocompromised Host", "Immunologics", "Individual", "Infection", "Knowledge", "Longevity", "Louisiana", "Malignant Neoplasms", "Measures", "Medicine", "Memory", "Methods", "Mission", "Pathogenesis", "Pathogenicity", "Patient-Focused Outcomes", "Patients", "Persons", "Plasma", "Recurrence", "Reporting", "Research", "Risk", "SARS-CoV-2 immunity", "Serology test", "Serum", "Special Population", "Survivors", "Systems Biology", "Technology", "Therapeutic", "Time", "Universities", "Vaccines", "Viral", "Viral Hemorrhagic Fevers", "Virus", "base", "biobank", "cell mediated immune response", "cohort", "convalescent plasma", "coronavirus disease", "human pathogen", "improved", "insight", "longitudinal analysis", "mortality", "neutralizing antibody", "novel", "personalized medicine", "prevent", "programs", "public health emergency", "response", "screening", "therapeutic evaluation", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "5246", "attributes": { "award_id": "3UM1AI108568-09S1", "title": "The Military HIV Research Program ( MHRP ) Clinical Trial Unit", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 18522, "first_name": "Gregg A,", "last_name": "Roby", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-02-11", "end_date": "2022-11-30", "award_amount": 42798, "principal_investigator": { "id": 18523, "first_name": "Julie A", "last_name": "Ake", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 18524, "first_name": "Merlin L", "last_name": "Robb", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 887, "ror": "", "name": "HENRY M. JACKSON FDN FOR THE ADV MIL/MED", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "COVID-19 Vaccine Clinical Development Team The USG enterprise to develop and optimize vaccine prevention modalities for SARS CoV-2 incorporates the DAIDS HVTN as a key partner in strategic development, research prioritization and execution, landscape analysis for future directions and analysis of outcomes. Dr. Robb has co-chaired and participated in the USG Vaccine Development Team for clinical research along with the PI and others within the HVTN. The administrative amendment to CTU funding to HJF will sustain Dr. Robb’s role in this capacity.", "keywords": [ "2019-nCoV", "Amendment", "COVID-19 vaccine", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Clinical Research", "Clinical Trials Network", "Clinical Trials Unit", "Consultations", "Elements", "Funding", "Future", "Group Meetings", "HIV", "HIV Vaccine Trials Network", "Leadership", "Military Personnel", "Modality", "Monoclonal Antibodies", "National Institute of Allergy and Infectious Disease", "Outcome", "Prevention", "Research", "Role", "Testing", "United States National Institutes of Health", "VTN gene", "Vaccines", "clinical development", "coronavirus disease", "meetings", "novel", "pre-clinical", "programs", "research and development", "vaccine development", "vaccine-induced antibodies" ], "approved": true } }, { "type": "Grant", "id": "10551", "attributes": { "award_id": "1R21HD105886-01A1", "title": "Assessing Children’s Learning Achievement Using Remote Video Technology", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 9683, "first_name": "REGINA M", "last_name": "BURES", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-30", "end_date": "2024-08-31", "award_amount": 234000, "principal_investigator": { "id": 26563, "first_name": "PAULA W", "last_name": "FOMBY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "This study evaluates remote video interviewing as a mode to administer standardized tests of math and reading achievement to children age 5-17 years in their homes. The goal is to determine whether remote video interviewing should be offered as an alternative mode of standardized test administration in the next wave of the Child Development Supplement (CDS) to the Panel Study of Income Dynamics and will provide evidence about whether this approach offers an equivalent alternative to costly in-person administration with geographically dispersed or otherwise hard-to-reach samples. Standardized tests of math and reading performance offer valid and reliable measurement of a critical dimension of child development and reveal socially patterned disparities in learning achievement. To date in CDS, these tests have been administered in- person during field interviewers’ visits to children’s homes. But in-person administration has become increasingly challenging due to high travel and staffing costs associated with these visits in the geographically dispersed sample, respondents’ selective resistance to home visits, and constraints on in-person data collection arising from COVID-19. This project implements and evaluates remote video interviewing as a method to administer subtests from the Woodcock-Johnson IV Tests of Achievement (WJ-IV) to children. Sample members will be recruited through local advertising in geographic clusters selected throughout the country and in different types of rural, suburban, and urban areas in proximity to where experienced interviewers reside. Remote video interviewing will be achieved by mailing (with a prepaid return shipping box) an electronic tablet enabled with a cellular data connection to children in sample families. During a scheduled interview, children will use the tablet to interact with their interviewer via a videoconferencing interface, and the interviewer will present test stimuli via a screenshare from their own computer to the child’s tablet. The interviewer will record the child’s responses to stimuli in a programmed scoresheet. This mode of administration will be compared to conventional in-person administration with the same children using distinct but equivalent versions of the WJ-IV tests. The study team will evaluate within-person equivalence of test scores derived from the two modes of administration and the operational feasibility and efficiency of remote video administration with regard to cost, time, and task complexity.", "keywords": [ "Adopted", "Advertising", "Age", "COVID-19", "COVID-19 pandemic", "Charge", "Child", "Child Development", "Child Welfare", "Complex", "Computers", "Country", "Data", "Data Collection", "Dimensions", "Elderly", "Employment", "Evaluation", "Exhibits", "Family", "Fostering", "Geography", "Goals", "Health", "Home", "Home visitation", "Income", "Interview", "Interviewer", "Learning", "Life", "Location", "Mathematics", "Measurement", "Measures", "Methods", "Neighborhoods", "Parents", "Participant", "Pathway interactions", "Pattern", "Performance", "Personal Satisfaction", "Persons", "Population", "Poverty", "Privacy", "Quantitative Reasoning", "Reading", "Research", "Research Support", "Resistance", "Resources", "Respondent", "Risk", "Running", "Rural", "Sampling", "Schedule", "Schools", "Shipping", "Social Distance", "Social Policies", "Standardization", "Stimulus", "Stress", "Sum", "Surveys", "Tablets", "Technology", "Testing", "Time", "Training", "Travel", "Validity and Reliability", "Variant", "Videoconferencing", "Visit", "Work", "achievement test", "cognitive skill", "cohort", "cost", "cost efficient", "data infrastructure", "design", "ethnic minority", "experience", "falls", "improved", "innovation", "intervention program", "learning ability", "learning outcome", "mathematical ability", "member", "panel study of income dynamics", "peer", "preference", "prevent", "racial and ethnic", "racial minority", "reading ability", "recruit", "response", "social", "socioeconomics", "standardize measure", "suburb", "success", "urban area" ], "approved": true } }, { "type": "Grant", "id": "10591", "attributes": { "award_id": "1R01AI170839-01", "title": "Human Herpesvirus 6B in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome pathogenesis: temporal analysis of viral reactivation and immunity to elucidate cause vs effect", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 22533, "first_name": "Christopher E.", "last_name": "Beisel", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-09", "end_date": "2027-08-31", "award_amount": 531652, "principal_investigator": { "id": 26618, "first_name": "Jackie", "last_name": "Cliff", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26619, "first_name": "Eliana", "last_name": "Lacerda", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1630, "ror": "", "name": "LONDON SCH/HYGIENE & TROPICAL MEDICINE", "address": "", "city": "", "state": "", "zip": "", "country": "UNITED KINGDOM", "approved": true }, "abstract": "/ ABSTRACT Our research project, entitled “Human Herpesvirus 6B in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome pathogenesis: temporal analysis of viral reactivation and immunity to elucidate cause vs effect”, aims to validate or refute the findings of our preliminary study on the role of human herpesviruses on the severity of symptoms in ME/CFS, and to determine if the virus reactivation is a cause or a consequence of the immune dysregulation. We will follow-up a larger number of consenting individuals (n=306), using our rigorous protocols designed to recruit participants to the UK ME/CFS Biobank (UKMEB). We have consent to re-contact UKMEB participants with ME/CFS (including those with a severe form of disease), and non-diseased controls (n=>500), with clinical assessments and collection of biosamples (blood and saliva). We will also recruit another comparison group, consisting of people with Long-COVID presenting with symptoms typical of ME/CFS (n=30), as well as people who did not develop long-term post-acute sequelae of COVID-19 after acute illness (Short COVID: n=30). The study population will comprise individuals from 18 - 60 years old, who have a diagnosis for ME/CFS or Long COVID with ME/CFS, as well as healthy controls and people who had Short COVID, in compliance with inclusion and exclusion criteria. We will perform a longitudinal analysis of people living with ME/CFS to determine the association and temporal relationship between HHV-6B DNA concentration and ME/CFS symptom severity, measuring viral DNA in saliva monthly for 6 months, alongside symptom scoring. To confirm that increases in HHV-6B DNA in saliva reflect systemic reactivation, we will measure blood viral RNA, DNA and protein, with the hypothesis that saliva RNA will correlate with saliva DNA concentration, and that all will increase together when ME/CFS symptoms are elevated. We will also measure frequency, phenotype and function of HHV-6B-reactive CD4+ and CD8+ T cells in people with ME/CFS. using flow cytometry, and will investigate the immunosuppressive effects of HHV-6B on antigen presentation in macrophages in ME/CFS using gene expression analysis. We hypothesize that HHV- 6B-specific T cells expand as ME/CFS symptoms worsen but are ineffective in for HHV-6B control, and we will test whether similar changes are observed in those with Long COVID in people who fulfill the diagnostic criteria for ME/CFS. Our goal, which stems from our successful pilot study, is to establish whether HHV-6B reactivation is causal in ME/CFS pathogenesis, and generate biological evidence which will inform targeted interventions such as vaccine development.", "keywords": [ "2019-nCoV", "Acute", "Adult", "Affect", "Antigen Presentation", "Antigen-Presenting Cells", "Bacterial Infections", "Biological", "Biological Assay", "Blood", "Blood specimen", "CD8-Positive T-Lymphocytes", "COVID-19", "Cell physiology", "Cells", "Characteristics", "Chemical Exposure", "Chronic Fatigue Syndrome", "Clinical", "Clinical assessments", "Collection", "Consent", "Cryopreservation", "DNA", "Data", "Data Collection", "Development", "Diagnosis", "Diagnostic tests", "Disease", "Endocrine", "Enrollment", "Etiology", "Event", "Evidence based treatment", "Exclusion Criteria", "Exertion", "Family member", "Fatigue", "Flow Cytometry", "Frequencies", "Funding", "Gene Expression Profiling", "Goals", "HHV-6B", "Herpesviridae", "Human", "Immune", "Immune response", "Immunity", "Immunologic Surveillance", "Immunologics", "Immunosuppression", "Individual", "Infection", "Interferon Type II", "Interleukin-2", "Intervention", "Knowledge", "Laboratories", "Life", "Long COVID", "Measures", "Multiple Sclerosis", "Mycoses", "Nature", "Outcome", "Participant", "Pathogenesis", "Patient Recruitments", "Peripheral Blood Mononuclear Cell", "Persons", "Phenotype", "Pilot Projects", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Prognostic Marker", "Proteins", "Protocols documentation", "RNA", "Recurrence", "Relapse", "Research Project Grants", "Role", "Saliva", "Salivary", "Severities", "Severity of illness", "Stress", "Symptoms", "Syndrome", "System", "T cell response", "T-Lymphocyte", "TNF gene", "Testing", "Time", "United States National Institutes of Health", "Viral", "Viral Markers", "Viral Proteins", "Virus", "Virus Diseases", "Work", "antigen-specific T cells", "base", "biobank", "clinical phenotype", "cohort", "comparison group", "coronavirus disease", "design", "diagnostic criteria", "digital", "epidemiology study", "follow-up", "inclusion criteria", "latent infection", "longitudinal analysis", "macrophage", "monocyte", "post SARS-CoV-2 infection", "recruit", "relating to nervous system", "saliva sample", "sample collection", "stem", "stressor", "study population", "vaccine development", "vaccine immunotherapy", "viral DNA", "viral RNA" ], "approved": true } } ], "meta": { "pagination": { "page": 5, "pages": 1442, "count": 14420 } } }